All News

Your daily dose of the clinical news you may have missed.

Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.

After a false positive breast cancer screening result, women may be reluctant to participate in future screening, a topic that could benefit from the primary care touch.

The FDA today accepted GSK's NDA for gepotidacin for the treatment of uncomplicated urinary tract infections in women and adolescents.

Caissa Troutman, MD, provides an overview of the connection between obesity and hypertension.

Your daily dose of the clinical news you may have missed.

Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.

Supported by Otsuka, new research calculated the value of daily hours spent on basic chores and complex tasks required to support a loved one with AD.

Antiobesity medications are the next step after lifestyle interventions prove inadequate; here are the American Gastroenterological Association recommendations, at-a-glance.

Your daily dose of the clinical news you may have missed.

Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.

A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.

Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals.

Higher alcohol intake was associated with a greater risk of gout for both sexes, but the correlation was stronger in men than women, according to a recent study.

The group of women least likely to return for a regular preventive screening mammogram after a false positive result surprised this primary investigator.

Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.

Your daily dose of the clinical news you may have missed.

The elinzanetant NDA is based on data, including long-term efficacy, from the OASIS phase 3 clinical trial program, according to Bayer.